Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications
about
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American CoReview of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryAspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published StudiesGastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatmentProinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic classDiabetes in older adultsRecommending aspirin for primary prevention in diabetic patients: what may we conclude from the data?Designing and implementing a comparative effectiveness study of two strategies for delivering high quality CHD prevention: methods and participant characteristics for the Heart to Health study.Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality.Individualized medical decision making: necessary, achievable, but not yet attainable.Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis.Development of a tool to improve the quality of decision making in atrial fibrillation.Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.Diabetes in older adults: a consensus reportAspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.Demographic, medical, and behavioral characteristics associated with over the counter non-steroidal anti-inflammatory drug use in a population-based cohort: results from the Multi-Ethnic Study of Atherosclerosis.Toxicity studies of a bioactive protein with antithrombotic-thrombolytic activity, DLBS1033.Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)Hospital physicians' influence on gastrointestinal protection during treatment with non-steroidal anti-inflammatory drugs and acetylsalicylic acid and the impact on prescribing in primary care.Cost-utility of aspirin and proton pump inhibitors for primary preventionRisk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes.Aspirin for primary prevention of cardiovascular disease in diabetes mellitusAnti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapySilent myocardial ischaemia and long-term coronary artery disease outcomes in apparently healthy people from families with early-onset ischaemic heart diseaseAspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis.Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancerAspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patientsBleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies.Decision Aids: The Effect of Labeling Options on Patient Choices and Decision MakingAdult Patients' Perspectives on the Benefits and Harms of Overused Screening Tests: a Qualitative Study.Antiplatelet therapy for every diabetic person?Clinical Risk Factors for Gastroduodenal Ulcer in Romanian Low-Dose Aspirin ConsumersEffect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in menAbsence of Helicobacter pylori is not protective against peptic ulcer bleeding in elderly on offending agents: lessons from an exceptionally low prevalence population.Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice.Gastrointestinal effects of aspirin.Advances in monitoring of aspirin therapy.Optimizing the use of aspirin for cardiovascular prevention.
P2860
Q22241289-7EEEDF11-0498-461E-B427-9A22426257F9Q22241777-FC270BD2-EEF8-4D6B-A414-30DCA7833943Q22241786-CE31E28E-9265-48B2-9E50-3C7B8894BF67Q26751511-075D42F0-4914-43A1-8E6A-43374127CC96Q27027977-8104D948-B776-4D34-AA60-CA95C19F36EAQ28292548-42999A39-3CD0-4597-945D-8B599837ABE6Q30528669-AEBCDD56-00CC-4AA0-A293-0C648A2119CAQ30582282-81592833-CA20-49B1-9B1D-3DB609D0B226Q30585262-D19F0169-4D2D-412F-AE73-1124ECA8CFC1Q33739341-2AE9101C-CD47-422F-81F9-00DFA24E3A5DQ33752536-F574CE44-AC37-4929-BBB0-E11A21060919Q33871754-4CA5D930-03A2-4C7D-B23D-E3D2319661BBQ34041787-3607369F-4DFD-47F9-958A-64F1E92D51C2Q34251380-1CCDCB95-291A-4E73-9664-A9C41379C792Q34308751-5866C2E0-D861-420E-9682-E05A3B796EDBQ34433987-31F52FB1-F8FC-4041-B131-40728CAA495AQ34460170-872BA9CA-113F-43CA-9A67-F8F69E19AE07Q34802353-099D03B2-C3B2-4684-934E-C195446DF2A6Q34935769-487ECECC-17D2-4AE6-8C6A-2E593AFBFDEAQ35069807-517C35E0-D3ED-4EF6-83DE-805CCBE76D7FQ35108108-28CC8C7A-2083-4F79-B197-F73C8B0DCA34Q35117393-BD859DD3-C195-4493-A3D8-5F485DC0C0F3Q35132896-8008AD63-311D-4A09-AA08-A12FF35F2C1CQ35373624-7FC09803-D65A-4F79-A063-8F5F609B3FC7Q35545802-A31FFBFD-A285-4339-91D9-28CC2BA210F8Q35685250-D1B2D2BD-A50F-4192-A769-EEC4612819F0Q35794066-2D856473-CA5F-4B4E-824B-D916A18C2192Q35991934-48E59CAD-FE2E-4A1C-AC53-C9E4B727D625Q36011124-6F814620-A03E-4A2C-BA42-B4DCBF5CBF9CQ36094923-B95A6C3C-CF1D-4750-8DBE-94F49A280529Q36117747-4D7E031B-9E7F-4D88-B2DC-7C17F4C6C375Q36199440-A0079B87-08ED-4A38-AD65-C571430C6BFDQ36783726-2D917747-AEE6-4796-96F3-56C77F6A04FAQ37192996-E2692877-5F33-4352-9743-57F7BA53A7ABQ37231429-3D5AF3CF-5D2B-465B-95A4-0CF9E3BF1597Q37599504-BB354DFA-037B-487E-BE9B-FA1B656783CFQ37774375-B263DFA5-4AA1-442E-AED2-60EA9BCC1634Q37885723-DE9F5177-2EE9-409B-9BA8-7EFC87832F10Q38032895-C78CCBB8-D986-4CAF-9FF3-07BD03E8D507Q38107179-0534C627-1101-49C8-8655-B8DAAD7F116B
P2860
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cardioprotective aspirin users ...... gastrointestinal complications
@ast
Cardioprotective aspirin users ...... gastrointestinal complications
@en
Cardioprotective aspirin users ...... gastrointestinal complications
@nl
type
label
Cardioprotective aspirin users ...... gastrointestinal complications
@ast
Cardioprotective aspirin users ...... gastrointestinal complications
@en
Cardioprotective aspirin users ...... gastrointestinal complications
@nl
prefLabel
Cardioprotective aspirin users ...... gastrointestinal complications
@ast
Cardioprotective aspirin users ...... gastrointestinal complications
@en
Cardioprotective aspirin users ...... gastrointestinal complications
@nl
P2860
P3181
P356
P1433
P1476
Cardioprotective aspirin users ...... gastrointestinal complications
@en
P2093
Luis A García Rodríguez
Sonia Hernández-Díaz
P2860
P2888
P3181
P356
10.1186/1741-7015-4-22
P407
P577
2006-09-20T00:00:00Z
P5875
P6179
1010687576